Highlights PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Real-time Estimate Cboe BZX Other stock markets 03:25:10 2024-04-29 pm EDT			5-day change	1st Jan Change
32.08 ^USD	+12.29%		+23.03%	+15.93%

12:14pm	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	MT
Apr. 26	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 26	MT
Sector Update: Health Care	Apr. 26	MT
PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results	Apr. 26	MT
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q1 Revenue $210.1M, vs. Street Est of $163.8M	Apr. 25	MT
PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Apr. 25	CI
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	Mar. 28	CI
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	Mar. 19	CI
PTC Therapeutics Shares Jump Following Q4 Results	Mar. 01	MT
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours	Feb. 29	MT
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q4 Revenue $307.1M, vs. Street Est of $317.9M	Feb. 29	MT
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Global markets live: LVMH, Intel, Tesla, Salesforce, Eli Lilly...	Jan. 26
Inflation is just the icing on the cake	Jan. 26
Stocks to Watch : Intel, PTC Therapeutics, KLA	Jan. 25	DJ
Europe to withdraw PTC Therapeutics' rare muscle disorder drug	Jan. 25	RE
PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing	Jan. 25	RE
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn Following Re-examination Procedure	Jan. 25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Highlights

Filters